Search results

Thought this was a third measure which they refer to as: "fibre fraction (NII-FF, indicating apparent axonal density)"

The Dutch autopsy study found none: Agree, but it does increase the risk of p-hacking because you can introduce several other variables into your model to see whether they lower the p-values. Same with this decision. This might be reasonable, but it also creates an opportunity to present...

Thanks Hutan and ScoutB, I was running into the same issues. Here's how I understand it: hindered water ratio (NII-HR) indicates places were water is very free to diffuse while restricted fraction (NII-RF) are places where water is very restricted to diffuse. In inflammation both measures are...

Looks like an application of AI in medicine that could actually be useful. The paper was published in Cell: Multimodal AI generates virtual population for tumor microenvironment modeling: Cell

'The convergence of digital transformation and the GenAI revolution creates an unprecedented opportunity for accelerating progress in precision health. Precision immunotherapy is a poster child for this transformation. Emerging technologies such as multiplex immunofluorescence (mIF) can assess...

Some comments I made myself: 1) New Polybio study reports: "We confirmed the persistence of SARS-CoV-2 Spike transcript and protein in the gut tissue of all LC cases and controls tested." So while RNA and proteins from the virus were present, these were found in controls as well. 2) The...

Some critical comments by immunologist Mark Veldhoen: https://bsky.app/profile/marcveld.bsky.social/post/3mgyxka7w3z2n

Some critical comments by Data Sleuth Sholto David

Here's what I got for tryptase-related genes on chromosome 16 (using GRCh38) And using locuszoom: Looks like my own code doesn't pick up on IGHE (position: chr14:105,597,691-105,601,728) for some reason but here's the data around that position. And here's the location on locuszoom with...

There were no signals at the p < 10^-6 level on chromosome 14 or 16.

Oxaloacetate is also listed with no mention of the conflicts of interest of the people who conducted these trials.

For antihistamines, no mention of this small RCT that trialled an older antihistamine terfenadine and got negative results. https://pubmed.ncbi.nlm.nih.gov/8568124/

For Modafinil, no mention of this negative (but very small) trial: https://pubmed.ncbi.nlm.nih.gov/16272188/

Same issue with IVIG where they mention " In ME/CFS, three studies reported positive outcomes" but this refers to case reports. They don't seem to mention the randomized trials that had negative results. https://pubmed.ncbi.nlm.nih.gov/2239975/ https://pubmed.ncbi.nlm.nih.gov/9236484/

The only randomized trial of Valganciclovir in ME/CFS had null results. https://pubmed.ncbi.nlm.nih.gov/23959519/ Also no mention here of the ME/CFS randomized trial that null results. https://www.nejm.org/doi/10.1056/NEJM198812293192602

The paper gives me the impression that they collected a lot of data but can't seem to make sense out of it themselves.

What were your reasons for thinking about IFN-gamma in ME/CFS, because it's crucial in the cytotoxic T-cell response against intracellular infection?

Made a social media summary about this study: 1) Interesting study showing that a brain infection in mice can lead to loss of synapses and altered excitability of neurons that outlasts the immune response against the virus. Changes are induced by interferon-gamma and involve epigenetic...

In my experience the biggest difference in prevalence estimates is not in the criteria and whether PEM is required but whether it is based on questionnaires or a medical examination by a physician who talks to the patient and checks for other plausible causes for the symptoms. The latter results...

Other studies that used the Fukuda criteria.